LUNG CANCER, NON-SMALL CELL

This phase 2/3 trial is testing whether adding two immunotherapy drugs (cobolimab and dostarlimab) to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. The study includes about 758 participants whose cancer has worsened after pri…

This phase 2 trial tests several new immunotherapy drug combinations in people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants have not had prior treatment for their advanced cancer. The main goal is to check the safety of the…

This Phase 3 trial tests whether combining two immune-boosting drugs (belrestotug and dostarlimab) works better than the standard treatment (pembrolizumab) for people with advanced non-small cell lung cancer that has high PD-L1 levels and hasn't been treated before. About 88 part…

This study compares three standard treatments for lung tumors: surgery, targeted radiation (SBRT), and minimally invasive thermal ablation (using heat or cold to destroy tumors). About 68 adults with early-stage lung cancer or limited lung metastases will be followed for two year…

This study tests a 12-week program called Breathe Easier+ for people who have finished treatment for non-small cell lung cancer and their partners. The program includes guided walking, resistance training, coaching calls, and stress management delivered remotely via smartphone or…

This study is testing whether providing medically tailored meals along with nutrition counseling can improve the health and well-being of lung cancer patients who are economically disadvantaged or from minority groups. About 299 patients from four U.S. medical centers will receiv…

This study tests a tool that helps patients with lung cancer or lung metastases work with their doctor to choose the right radiation dose. The tool is designed for tumors very close to the chest wall. The goal is to see if using this tool leads to better shared decision-making an…